Rate My Professor Keith Chappell

Professor Keith Chappell is a molecular virologist holding a dual appointment as Professor at the Australian Institute for Bioengineering and Nanotechnology and the School of Chemistry and Molecular Biosciences in the Faculty of Science at the University of Queensland. He earned a Bachelor of Science and Doctor of Philosophy from the University of Queensland, completing his PhD in 2007 on the structure and function of flavivirus NS3 protease. From 2007 to 2010, he served as a postdoctoral researcher at Instituto de Salud Carlos III in Spain, investigating the Respiratory Syncytial Virus fusion protein as a target for conformation-specific neutralizing antibodies. Upon returning to UQ in 2011, his career has centered on vaccine development and research into medically and environmentally significant viruses and bacteria, including Influenza, Respiratory Syncytial Virus, SARS-CoV-2, Koala Retrovirus, Streptococcus pneumoniae, Nipah virus, and HTLV-1. As group leader of the 12-member Chappell Group, he drives innovative projects in structural virology and rapid vaccine responses.

Chappell is a co-inventor of UQ's molecular clamp platform and its second-generation iteration, which resolved diagnostic interference issues for the UQ COVID-19 vaccine candidate. He co-led the UQ COVID-19 vaccine program, implementing an epidemic response pipeline that advanced from viral sequence to clinical trial dosing in six months. He leads UQ's Coalition for Epidemic Preparedness Innovations-funded Rapid Response Vaccine Pipeline to counter future pandemics and acts as Lead Scientific Advisor for UQ spinout Vicebio, advancing molecular clamp-stabilized vaccines for respiratory viruses such as RSV toward clinical trials. His influential publications include the phase 1 trial of an MF59-adjuvanted SARS-CoV-2 spike glycoprotein-clamp vaccine (The Lancet Infectious Diseases, 2021), 12-month safety and immunogenicity results (eBioMedicine, 2023), Nipah virus vaccines in pigs (npj Vaccines, 2025), HTLV-1 reverse transcriptase modeling (Virology Journal, 2024), and koala retrovirus evolution studies (Cell, 2025). His contributions have shaped global vaccine strategies for emerging threats.